Spotlight Innovation Inc. announced Monday that it completed the acquisition of a majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville. Memcine Pharmaceuticals is developing its Immunoplex vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa. Based in West Des Moines, Spotlight Innovation specializes in identifying, acquiring and incubating companies which have unique intellectual property in the medical sector. “…We look forward to furthering the development and fulfilling the promise of this exciting, potentially life-saving technology,” Spotlight Innovation CEO Cris Grunewald said in a release.